# A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies

> **NCT01805375** · PHASE1 · COMPLETED · sponsor: **Cancer Research UK** · enrollment: 28 (actual)

## Conditions studied

- Indolent B-cell Lymphoma
- Chronic Lymphocytic Leukaemia
- Waldenström Macroglobulinaemia

## Interventions

- **DRUG:** DI-B4

## Key facts

- **NCT ID:** NCT01805375
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2017-12-14
- **Final completion:** 2017-12-14
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01805375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01805375, "A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01805375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*